Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Stanley Liauw

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentRadiation & Cellular Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Stanley Liauw serves as the Director of Clinical Operations and is the clinical lead for the genitourinary (GU) cancer program and the gastrointestinal (GI) cancer program within the Department of Radiation and Cellular Oncology at the University of Chicago. In the past 10 years on faculty, Dr. Liauw has developed research programs in these disease sites, with an interest in outcomes research and clinical trials. The central mission of his research is to conduct clinical studies to define current clinical outcomes and areas of need, develop hypotheses, and test novel regimens to reduce the morbidity or mortality of radiation therapy in the treatment of cancer.

    A major focus of Dr. Liauw's efforts include the periodic analysis and reporting of cancer outcomes with radiation therapy. This work, derived from multiple institutional databases of more than 2000 patients, has resulted in numerous abstract presentations and publications in peer-reviewed journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, Physics and Cancer. These contributions generally fall into 3 categories of interest: presenting hypotheses to improve the therapeutic ratio of therapy, studying the use of imaging in radiation oncology, and exploring potential markers of response to therapy.

    A number of clinical protocols have been opened for patients with genitourinary and gastrointestinal cancers. Dr. Liauw has investigated and initiated trials for a: phase I study of dose escalated stereotactic body RT trial for unresectable pancreatic cancer, phase II quality of life study of oral hormonal therapy with RT for prostate cancer, phase I study for oligometastatic renal cell cancer, and phase I randomized study for hepatocellular carcinoma treated with RT and immunotherapy.

    Outside of his research interests, Dr. Liauw has overseen several intradepartmental projects aimed at improving clinical workflow and patient safety, with potential downstream effects on patient and employee satisfaction. He served as the clinical lead for the implementation of intraoperative radiation therapy in 2015, as an Associate Editor for GI cancers for the International Journal of Radiation Oncology, Biology, and Physics, as an examiner and question writer for the American Board of Radiology for GU cancers, and an invited speaker for national and international educational lectures such as through the American Society of Radiation Oncology (ASTRO) and the American Urological Association. He has been an invited Visiting Professor for resident education at multiple institutions, and has been regularly recognized from the University of Chicago training program as a top educator. He has been an ad hoc reviewer of manuscripts for more than 20 scientific journals, including Journal of Clinical Oncology and the New England Journal of Medicine.


    Collapse Biography 
    Collapse education and training
    MIT, Cambridge, MABS6/1997Chemical Engineering
    UT Southwestern Medical School, Dallas, TXMD6/2001Medicine
    Brigham and Women's Hospital, Boston, MAInternship6/2002Internal Medicine
    University of Florida, Gainesville, FLResidency6/2006Radiation Oncology

    Collapse ORNG Applications 
    Collapse Twitter
    Collapse Websites

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, Gilligan T, Karam JA, Leibovich B, Liauw SL, Masterson TA, Meeks JJ, Pierorazio PM, Sharma R, Sheinfeld J. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281. PMID: 31059667.
      View in: PubMed
    2. Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, Heath EI, Liauw S, Spratt DE, Hung AY, Antonarakis ES, Tran PT. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer. 2019 Jun 13; 19(1):572. PMID: 31196032.
      View in: PubMed
    3. Akthar AS, Liao C, Eggener SE, Liauw SL. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 May 19. PMID: 31113644.
      View in: PubMed
    4. Reddy AV, Golden DW, Brower JV, Liauw SL. Regional Influence of Radiation Oncology Residency Training on Job Securement over Two Time Periods. Cureus. 2019 Apr 18; 11(4):e4495. PMID: 31259113.
      View in: PubMed
    5. Foster B, Jackson W, Foster C, Dess R, Abu-Isa E, McLaughlin PW, Merrick G, Hearn J, Spratt D, Liauw S, Hamstra D. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. Am J Clin Oncol. 2019 Apr; 42(4):382-390. PMID: 30724780.
      View in: PubMed
    6. Jothishankar B, Almazan T, Kim Y, Liauw S, Smith S, Kline J, Abdulla F. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome. Br J Haematol. 2019 Jul; 186(2):377-379. PMID: 30937886.
      View in: PubMed
    7. Reddy AV, Mills MN, Liauw SL, Baliga S, Kersh CR. Long term control and preservation of renal function after multiple courses of stereotactic body radiation therapy for renal cell carcinoma. Can J Urol. 2019 Apr; 26(2):9743-9745. PMID: 31012841.
      View in: PubMed
    8. Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18. PMID: 30392939.
      View in: PubMed
    9. Kauffmann G, Arif F, Patel P, Oto A, Liauw SL. Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urol Oncol. 2018 10; 36(10):471.e11-471.e18. PMID: 30122344.
      View in: PubMed
    10. Son CH, Liauw SL, Hasan Y, Solanki AA. Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):304-313. PMID: 29908944.
      View in: PubMed
    11. Foster CC, Lee AY, Furtado LV, Hart J, Alpert L, Xiao SY, Hyman NH, Sharma MR, Liauw SL. Correction: Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. PLoS One. 2018; 13(7):e0200400. PMID: 29975772.
      View in: PubMed
    12. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 May 10; 4(5):e175230. PMID: 29372236.
      View in: PubMed
    13. Akthar AS, Wong AC, Parekh AD, Hubert G, Son CH, Pelizzari CA, Liauw SL. Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines. Adv Radiat Oncol. 2018 Jul-Sep; 3(3):339-345. PMID: 30202803.
      View in: PubMed
    14. Foster CC, Lee AY, Furtado LV, Hart J, Alpert L, Xiao SY, Hyman NH, Sharma MR, Liauw SL. Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. PLoS One. 2018; 13(3):e0194234. PMID: 29522569.
      View in: PubMed
    15. Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 12; 20(4):442. PMID: 29125150.
      View in: PubMed
    16. Apisarnthanarax S, Jabbour SK, Liauw SL, Murphy JD, Olsen JR, Chang DT. Gastrointestinal Cancers: Timing Is Everything. Int J Radiat Oncol Biol Phys. 2017 12 01; 99(5):1051-1058. PMID: 29165271.
      View in: PubMed
    17. Ying J, Wang CJ, Yan J, Liauw SL, Straka C, Pistenmaa D, Xie XJ, Lotan Y, Roehrborn C, Kim DN. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2017 Dec; 40(6):612-620. PMID: 26165416.
      View in: PubMed
    18. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2018 07; 74(1):99-106. PMID: 29128208.
      View in: PubMed
    19. Rodriguez JF, Liauw SL, Eggener SE. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. Urol Clin North Am. 2017 Nov; 44(4):597-609. PMID: 29107276.
      View in: PubMed
    20. Clements MB, Schmidt KM, Canfield SE, Gilbert SM, Khandelwal SR, Koontz BF, Lallas CD, Liauw S, Nguyen PL, Showalter TN, Trabulsi EJ, Cathro HP, Schenkman NS, Krupski TL. Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. J Surg Educ. 2018 Mar - Apr; 75(2):434-441. PMID: 28923535.
      View in: PubMed
    21. Liauw SL. A Pancreatic Predicament. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):296-297. PMID: 28871973.
      View in: PubMed
    22. Son CH, Hamstra DA, Feng FY, Liauw SL. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352. PMID: 25436827.
      View in: PubMed
    23. Kauffmann G, Liauw SL. The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update. Curr Urol Rep. 2017 Jul; 18(7):50. PMID: 28589396.
      View in: PubMed
    24. Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288. PMID: 28631720.
      View in: PubMed
    25. Brower JV, Liauw SL, Reddy AV, Golden DW. Radiation oncology residency selection: A postgraduate evaluation of factor importance and survey of variables associated with job securement. Pract Radiat Oncol. 2017 Nov - Dec; 7(6):425-432. PMID: 28666900.
      View in: PubMed
    26. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):437-454. PMID: 29114613.
      View in: PubMed
    27. McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol. 2017 02; 40(1):1-10. PMID: 28059930.
      View in: PubMed
    28. Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276. PMID: 27964905.
      View in: PubMed
    29. Reddy AV, Christodouleas JP, Wu T, Smith ND, Steinberg GD, Liauw SL. External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):740-746. PMID: 28244409.
      View in: PubMed
    30. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84. PMID: 28740916.
      View in: PubMed
    31. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3648-3654. PMID: 27528718.
      View in: PubMed
    32. Lee AY, Golden DW, Bazan JG, Kopec M, Pelizzari CA, Aggarwal S, Chang DT, Liauw SL. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):306-312. PMID: 28068238.
      View in: PubMed
    33. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053. PMID: 27745980.
      View in: PubMed
    34. Apisarnthanarax S, Chia-Hsien Cheng J, Jabbour SK, Liauw SL, Murphy JD, Chang DT. Gastrointestinal Cancers-Changing the Standard for Rectal Cancer and Establishing a New Standard for Liver Tumors. Int J Radiat Oncol Biol Phys. 2016 07 01; 95(3):930-6. PMID: 27302509.
      View in: PubMed
    35. Liauw SL, Reddy AV, Weichselbaum RR, Smith ND, Steinberg GD. In Reply to Zaghloul. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):855. PMID: 27131088.
      View in: PubMed
    36. Liauw SL, Kropp LM, Dess RT, Oto A. Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urol Oncol. 2016 09; 34(9):416.e15-21. PMID: 27241167.
      View in: PubMed
    37. Gunther JR, Liauw SL, Choi S, Mohamed AS, Thaker NG, Fuller CD, Stepaniak CJ, Das P, Golden DW. A Prostate Fossa Contouring Instructional Module: Implementation and Evaluation. J Am Coll Radiol. 2016 Jul; 13(7):835-841.e1. PMID: 27210232.
      View in: PubMed
    38. Vikram R, Beland MD, Blaufox MD, Moreno CC, Gore JL, Harvin HJ, Heilbrun ME, Liauw SL, Nguyen PL, Nikolaidis P, Preminger GM, Purysko AS, Raman SS, Taffel MT, Wang ZJ, Weinfeld RM, Remer EM, Lockhart ME. ACR Appropriateness Criteria Renal Cell Carcinoma Staging. J Am Coll Radiol. 2016 May; 13(5):518-25. PMID: 27016804.
      View in: PubMed
    39. Son CH, Melotek JM, Liao C, Hubert G, Pelizzari CA, Eggener SE, Liauw SL. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):e179-e185. PMID: 26961716.
      View in: PubMed
    40. Reddy AV, Pariser JJ, Pearce SM, Weichselbaum RR, Smith ND, Steinberg GD, Liauw SL. Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):1031-9. PMID: 27026309.
      View in: PubMed
    41. Chang DT, Jabbour SK, Brunner T, Cheng JC, Liauw SL, Meyer J, Wo J. Key New Studies in Gastric and Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):475-81. PMID: 26460987.
      View in: PubMed
    42. Melotek JM, Liao C, Liauw SL. Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes. PLoS One. 2015; 10(10):e0141639. PMID: 26512986.
      View in: PubMed
    43. Pearce SM, Liauw SL, Eggener SE. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98. PMID: 26216816.
      View in: PubMed
    44. Chang DT, Brunner T, Cheng JC, Liauw SL, Meyer J, Wo JY. Randomized trials and new directions in gastrointestinal cancer. Int J Radiat Oncol Biol Phys. 2015 Mar 01; 91(3):459-64. PMID: 25680590.
      View in: PubMed
    45. Kumar KA, Wu T, Tonlaar N, Stepaniak C, Yenice KM, Liauw SL. Image-guided radiation therapy for prostate cancer: A computed tomography-based assessment of fiducial marker migration between placement and 7 days. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):241-7. PMID: 25543198.
      View in: PubMed
    46. Son CH, Chennupati SK, Kunnavakkam R, Liauw SL. The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 May-Jun; 5(3):e223-8. PMID: 25491179.
      View in: PubMed
    47. Chang DT, Brunner T, Cheng JC, Liauw S, Meyer J, Wo J. Oncology scan-novel treatment strategies for gastrointestinal cancers. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):699-703. PMID: 24969787.
      View in: PubMed
    48. Corbin KS, Kindler HL, Liauw SL. Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther. 2014; 7:713-8. PMID: 24872712.
      View in: PubMed
    49. Chennupati SK, Pelizzari CA, Kunnavakkam R, Liauw SL. Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med. 2014 Aug; 3(4):954-61. PMID: 24803087.
      View in: PubMed
    50. Tonlaar N, Song S, Hong JC, Minsky BD, Chang DT, Polite BN, Liauw SL. Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race. Am J Clin Oncol. 2014 Apr; 37(2):122-5. PMID: 23211225.
      View in: PubMed
    51. Liu GF, Bair RJ, Bair E, Liauw SL, Koshy M. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. PLoS One. 2014; 9(1):e82642. PMID: 24416146.
      View in: PubMed
    52. Ranck MC, Golden DW, Corbin KS, Hasselle MD, Liauw SL, Stadler WM, Hahn OM, Weichselbaum RR, Salama JK. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95. PMID: 22868242.
      View in: PubMed
    53. Solanki AA, Chang DT, Liauw SL. Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. Onco Targets Ther. 2013; 6:1097-110. PMID: 23983475.
      View in: PubMed
    54. Solanki AA, Liauw SL. Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. Cancer. 2013 Aug 01; 119(15):2807-14. PMID: 23633434.
      View in: PubMed
    55. Macomber MW, Mullane KM, Liauw SL. Herpes zoster and radiation therapy: what radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster. Pract Radiat Oncol. 2014 Jan-Feb; 4(1):58-64. PMID: 24621425.
      View in: PubMed
    56. Kalakota K, Liauw SL. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology. 2013 Jun; 81(6):1196-201. PMID: 23540863.
      View in: PubMed
    57. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013 Feb 20; 5(173):173sr2. PMID: 23427246.
      View in: PubMed
    58. Choe KS, Liauw SL. Effects of aspirin on cancer initiation and progression. Expert Rev Anticancer Ther. 2013 Feb; 13(2):115-7. PMID: 23406550.
      View in: PubMed
    59. Semenenko VA, Tarima SS, Devisetty K, Pelizzari CA, Liauw SL. Validation of normal tissue complication probability predictions in individual patient: late rectal toxicity. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1103-9. PMID: 23021435.
      View in: PubMed
    60. Golden DW, Novak CJ, Minsky BD, Liauw SL. Radiation dose =54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiat Oncol. 2012 Sep 13; 7:156. PMID: 22974515.
      View in: PubMed
    61. Lee AY, Wu T, Vannier MW, Testa G, Liauw SL. Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability. J Gastrointest Cancer. 2012 Sep; 43 Suppl 1:S202-7. PMID: 22492210.
      View in: PubMed
    62. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 01; 30(28):3540-4. PMID: 22927523.
      View in: PubMed
    63. Liauw SL, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto A. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84. PMID: 22717242.
      View in: PubMed
    64. Corbin KS, Kunnavakkam R, Eggener SE, Liauw SL. Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):138-44. PMID: 24674317.
      View in: PubMed
    65. Ali AN, Rossi PJ, Godette KD, Martin D, Liauw S, Vijayakumar S, Cooper S, Jani AB. Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity modulated radiation therapy. Pract Radiat Oncol. 2013 Jan-Mar; 3(1):e1-e9. PMID: 24674267.
      View in: PubMed
    66. Song S, Hong JC, McDonnell SE, Koong AC, Minsky BD, Chang DT, Liauw SL. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012 Aug; 19(8):2471-6. PMID: 22327251.
      View in: PubMed
    67. Edelman S, Liauw SL, Rossi PJ, Cooper S, Jani AB. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1473-9. PMID: 22245201.
      View in: PubMed
    68. Song S, Yenice KM, Kopec M, Liauw SL. Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: a report of total setup error, required PTV expansion, and dosimetric implications. Radiother Oncol. 2012 May; 103(2):270-4. PMID: 21890224.
      View in: PubMed
    69. Solanki AA, Liauw SL. Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Open Access J Urol. 2011 Jun 15; 3:95-104. PMID: 24198641.
      View in: PubMed
    70. Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):235-41. PMID: 21163587.
      View in: PubMed
    71. Terakedis BE, Rossi PJ, Liauw SL, Johnstone PA, Jani AB. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol. 2010 Dec; 33(6):619-23. PMID: 20051808.
      View in: PubMed
    72. Liauw SL, Liauw SH. Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):751-7. PMID: 20932666.
      View in: PubMed
    73. Choe KS, Liauw SL. Radiotherapeutic strategies in the management of low-risk prostate cancer. ScientificWorldJournal. 2010 Sep 14; 10:1854-69. PMID: 20852828.
      View in: PubMed
    74. Malik R, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys. 2011 Jul 15; 80(4):1080-6. PMID: 20643513.
      View in: PubMed
    75. Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010 Aug; 7(8):437-47. PMID: 20628346.
      View in: PubMed
    76. Malik R, Jani AB, Liauw SL. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Mar 15; 79(4):1022-8. PMID: 20510547.
      View in: PubMed
    77. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9. PMID: 20421534.
      View in: PubMed
    78. Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010 Apr 01; 116(7):1820-6. PMID: 20143436.
      View in: PubMed
    79. Jani AB, Johnstone PA, Liauw SL, Master VA, Rossi PJ. Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis. Am J Clin Oncol. 2010 Apr; 33(2):168-72. PMID: 19745696.
      View in: PubMed
    80. Devisetty K, Zorn KC, Katz MH, Jani AB, Liauw SL. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1060-5. PMID: 20045267.
      View in: PubMed
    81. Kalakota K, Rakhno E, Pelizzari CA, Jani AB, Liauw SL. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis. Brachytherapy. 2010 Apr-Jun; 9(2):131-6. PMID: 19853533.
      View in: PubMed
    82. Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30. PMID: 19695789.
      View in: PubMed
    83. Liauw SL, Weichselbaum RR, Rash C, Correa D, Al-Hallaq HA, Pelizzari CA, Jani AB. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat. 2009 Jun; 8(3):201-6. PMID: 19445537.
      View in: PubMed
    84. Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):755-60. PMID: 19464123.
      View in: PubMed
    85. Liauw SL, Fricano J, Correa D, Weichselbaum RR, Jani AB. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer. 2009 Apr 15; 115(8):1784-90. PMID: 19208426.
      View in: PubMed
    86. Gutt R, Liauw SL, Weichselbaum RR. Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):38-46. PMID: 19029997.
      View in: PubMed
    87. Jani AB, Johnstone PA, Liauw SL, Master VA, Brawley OW. Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol. 2008 Aug; 31(4):375-8. PMID: 18845997.
      View in: PubMed
    88. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. 2008 Dec; 72(6):1298-302; discussion 1302-4. PMID: 18672274.
      View in: PubMed
    89. Yeung AR, Liauw SL, Amdur RJ, Mancuso AA, Hinerman RW, Morris CG, Villaret DB, Werning JW, Mendenhall WM. Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection? Cancer. 2008 Mar 01; 112(5):1076-82. PMID: 18186495.
      View in: PubMed
    90. Liauw SL, Minsky BD. The use of capecitabine in the combined-modality therapy for rectal cancer. Clin Colorectal Cancer. 2008 Mar; 7(2):99-104. PMID: 18501068.
      View in: PubMed
    91. Liauw SL, Weichselbaum RR, Zagaja GP, Jani AB. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1316-21. PMID: 18234446.
      View in: PubMed
    92. Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007 Oct 10; 25(29):4581-6. PMID: 17925552.
      View in: PubMed
    93. Liauw SL, Amdur RJ, Morris CG, Werning JW, Villaret DB, Mendenhall WM. Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck. Head Neck. 2007 Aug; 29(8):715-9. PMID: 17274056.
      View in: PubMed
    94. Jani AB, Liauw SL, Blend MJ. The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res. 2007 Jun; 5(2):123-31. PMID: 17607048.
      View in: PubMed
    95. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20; 25(15):2035-41. PMID: 17513807.
      View in: PubMed
    96. Jani AB, Master VA, Rossi PJ, Liauw SL, Johnstone PA. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 2007; 10(4):347-51. PMID: 17505529.
      View in: PubMed
    97. Liauw SL, Mancuso AA, Morris CG, Amdur RJ, Mendenhall WM. Definitive radiotherapy for head-and-neck cancer with radiographically positive retropharyngeal nodes: incomplete radiographic response does not necessarily indicate failure. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1017-21. PMID: 17145530.
      View in: PubMed
    98. Liauw SL, Byer JE, Yachnis AT, Amdur RJ, Mendenhall WM. Radiotherapy after subtotally resected or recurrent ganglioglioma. Int J Radiat Oncol Biol Phys. 2007 Jan 01; 67(1):244-7. PMID: 17045420.
      View in: PubMed
    99. Liauw SL, Yeh AM, Morris CG, Olivier KR, Mendenhall NP. Whole-abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1440-5. PMID: 16997504.
      View in: PubMed
    100. Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):669-73. PMID: 16887293.
      View in: PubMed
    101. Liauw SL, Mancuso AA, Amdur RJ, Morris CG, Villaret DB, Werning JW, Mendenhall WM. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol. 2006 Mar 20; 24(9):1421-7. PMID: 16549836.
      View in: PubMed
    102. Liauw SL, Amdur RJ, Mendenhall WM, Palta J, Kim S. The effect of intravenous contrast on intensity-modulated radiation therapy dose calculations for head and neck cancer. Am J Clin Oncol. 2005 Oct; 28(5):456-9. PMID: 16199983.
      View in: PubMed
    103. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004 Mar 17; 291(11):1325-32. PMID: 15026399.
      View in: PubMed
    104. Liauw SL, Benda RK, Morris CG, Mendenhall NP. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer. 2004 Mar 01; 100(5):920-8. PMID: 14983486.
      View in: PubMed
    105. Liauw SL, Webster WS, Pistenmaa DA, Roehrborn CG. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology. 2003 Jun; 61(6):1204-10. PMID: 12809898.
      View in: PubMed
    Liauw's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _